Stevens Capital Management LP purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, Holdings Channel reports. The fund purchased 27,274 shares of the medical device company’s stock, valued at approximately $3,901,000.
Other large investors have also modified their holdings of the company. Stratos Wealth Partners LTD. bought a new stake in DexCom during the 3rd quarter worth about $124,000. IBM Retirement Fund bought a new stake in shares of DexCom in the 3rd quarter valued at about $203,000. Brighton Jones LLC bought a new stake in shares of DexCom in the 3rd quarter valued at about $204,000. Strs Ohio bought a new stake in shares of DexCom in the 3rd quarter valued at about $213,000. Finally, 1ST Source Bank bought a new stake in shares of DexCom in the 3rd quarter valued at about $230,000.
DXCM has been the topic of a number of research analyst reports. Northland Securities raised shares of DexCom from an “under perform” rating to a “market perform” rating in a report on Wednesday, September 12th. Raymond James upped their target price on shares of DexCom from $125.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, October 23rd. Oppenheimer set a $150.00 target price on shares of DexCom and gave the company a “buy” rating in a report on Wednesday, November 7th. BidaskClub raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 21st. Finally, Piper Jaffray Companies upped their target price on shares of DexCom to $157.00 and gave the company an “overweight” rating in a report on Wednesday, November 7th. Nine analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $132.65.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.29. The firm had revenue of $266.70 million for the quarter, compared to analysts’ expectations of $242.72 million. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. DexCom’s quarterly revenue was up 44.5% on a year-over-year basis. As a group, equities analysts forecast that DexCom, Inc. will post -0.12 earnings per share for the current fiscal year.
In other DexCom news, CEO Kevin R. Sayer sold 25,495 shares of the stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $143.62, for a total value of $3,661,591.90. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Richard Doubleday sold 1,736 shares of the stock in a transaction dated Friday, November 23rd. The shares were sold at an average price of $121.35, for a total transaction of $210,663.60. Following the completion of the transaction, the executive vice president now directly owns 66,804 shares in the company, valued at $8,106,665.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 149,745 shares of company stock worth $21,210,998. Insiders own 1.80% of the company’s stock.
WARNING: “27,274 Shares in DexCom, Inc. (DXCM) Acquired by Stevens Capital Management LP” was published by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2018/12/02/27274-shares-in-dexcom-inc-dxcm-acquired-by-stevens-capital-management-lp.html.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: What are the risks of holding treasury bonds?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.